Abstract | OBJECTIVE: METHODS: We retrospectively evaluated the short-term efficacy and tolerance of rituximab in patients with various autoimmune diseases who were treated at the Hospital Israelita Albert Einstein in the city of Sao Paulo. RESULTS: CONCLUSION:
Rituximab seems to be safe and effective in the treatment of patients with a variety of autoimmune diseases that are refractory to other modalities of treatment.
|
Authors | M Scheinberg, N Hamerschlak, J M Kutner, A A F Ribeiro, E Ferreira, J Goldenberg, M H Kiss, W H Chahade |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2006 Jan-Feb
Vol. 24
Issue 1
Pg. 65-9
ISSN: 0392-856X [Print] Italy |
PMID | 16539821
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Immunologic Factors
- Rituximab
|
Topics |
- Adolescent
- Adult
- Aged
- Anemia, Hemolytic, Autoimmune
(diagnosis, drug therapy, physiopathology)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
- Arthritis, Rheumatoid
(diagnosis, drug therapy, physiopathology)
- Autoimmune Diseases
(diagnosis, drug therapy, physiopathology)
- Brazil
- Child
- Drug Therapy, Combination
- Female
- Humans
- Immunologic Factors
(therapeutic use)
- Lupus Erythematosus, Systemic
(diagnosis, drug therapy, physiopathology)
- Male
- Middle Aged
- Purpura, Thrombocytopenic, Idiopathic
(diagnosis, drug therapy, physiopathology)
- Retrospective Studies
- Rituximab
- Treatment Outcome
|